Business Wire: ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with ...
ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with ...
Nasdaq: ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd ...
LOTIS 3 interim results highlight potential of Lonca in combination with ibrutinib in relapsed or refractory diffuse large B-cell lymphoma and mantle cell lymphoma patients Preliminary pivotal Cami ...
ADC Therapeutics Announces Updated Clinical Data on Lead Antibody Drug Conjugate Programs Loncastuximab Tesirine (Lonca) and Camidanlumab Tesirine (Cami) Presented at 62nd ...
At YER, you can turn to us for secondment and recruitment and selection services. Realize your ambitions and explore the possibilities.
Bij YER kun je terecht voor detachering, werving en selectie. Realiseer je ambities en ontdek de mogelijkheden.
Discover everything about how YER originated, what we stand for, and what we aim for when working with us as a candidate or client.
Op zoek naar de nieuwste vacatures? YER helpt jou in het realiseren van jouw ambities. Neem een kijkje in ons uitgebreide aanbod en vind jouw droombaan.
Discover how YER can help you elevate your career and take it to the next level. YER is there for professionals seeking growth and development.
YER biedt ondersteuning aan starters die willen groeien op de arbeidsmarkt. Lees alles over YER voor starters op onze website en ontdek hoe we je helpen.